drugset / Trial / NCT07110883

A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

NCT07110883

Phase 1 Recruiting 400 enrolled CSPC Megalith Biopharmaceutical Co.,Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, dose-escalation and cohort-expansion, multicenter Phase I study involving participants with advanced solid tumors.

Timeline

Start
2024-08-15
Primary completion
2026-10-31
Completion
2028-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SYS6023 Other / unclassified 0.5 mg/kg Intravenous
Subject SYS6023 Other / unclassified 6.5 mg/kg Intravenous

Indications